Europe Peptide Therapeutics Market Size & Outlook
Related Markets
Europe peptide therapeutics market highlights
- The Europe peptide therapeutics market generated a revenue of USD 21,320.7 million in 2023.
- The market is expected to grow at a CAGR of 10.9% from 2024 to 2030.
- In terms of segment, metabolic disorders was the largest revenue generating application in 2023.
- Metabolic disorders is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Norway is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 21,320.7 million |
| Market revenue in 2030 | USD 43,925.4 million |
| Growth rate | 10.9% (CAGR from 2023 to 2030) |
| Largest segment | Metabolic disorders |
| Fastest growing segment | Metabolic disorders |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cancer, Metabolic disorders, Cardiovascular disorders, Respiratory disorders, Gastrointestinal disorders, Infectious disease, Pain, Dermatological disorders, Neurological disorders, Renal disorders |
| Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Amgen Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, Sanofi SA, Roche Holding AG, Novartis AG ADR, Novo Nordisk A/S ADR, GlaxoSmithKline, Ironwood Pharmaceuticals Inc Class A, Ipsen SA, Radius Health |
Other key industry trends
- In terms of revenue, Europe region accounted for 22.7% of the global peptide therapeutics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 172,089.8 million by 2030.
Metabolic disorders was the largest segment with a revenue share of 59.44% in 2023. Horizon Databook has segmented the Europe peptide therapeutics market based on cancer, metabolic disorders, cardiovascular disorders, respiratory disorders, gastrointestinal disorders, infectious disease, pain, dermatological disorders, neurological disorders, renal disorders covering the revenue growth of each sub-segment from 2018 to 2030.
Europe held the second-largest market share in 2023 after North America and is estimated to grow at a lucrative CAGR over the forecast period. This growth can be attributed to increased research funding and the presence of key market players in this region. Increasing investments are driving the number of biopharmaceutical companies in Europe.
This population is at a relatively high risk of developing various target diseases, including cancer, cardiovascular diseases, & neurological disorders, as the risk of developing these conditions and hospitalization rates are relatively higher in elderly patients. Thus, owing to the abovementioned factors, the region is expected to witness exponential growth opportunities during the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Peptide Therapeutics Market Scope
Peptide Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe peptide therapeutics market size, by country, 2018-2030 (US$M)
Europe Peptide Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
